Skip to content

Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients

Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00335517
Acronym
DepoDur
Enrollment
98
Registered
2006-06-12
Start date
2006-06-30
Completion date
2010-11-30
Last updated
2014-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Spine Surgery

Keywords

Lumbar surgery, Surgery L3-S1, DepoDur, Post-operative pain, Pain control, Pain relief

Brief summary

The purpose of the study is to help determine the appropriate dose of DepoDur for use in spinal surgery. The study will also assess the safety of this drug in this patient population.

Detailed description

Patients will be recruited from the general practices of Drs. Rechtine, Rubery, Molinari, and Zeidman. An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4 cm to L1 level prior to injection. Two milliliters of air will be injected through the catheter to ensure patency. Aspiration will then be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDurTM will be injected. The type of surgery will be recorded as to 1. The number of levels of surgery. 2. The number of levels fused 3. The number of levels instrumented. 4. The number of levels with an interbody fusion 5. Time to ambulate 6. Time to use oral analgesics 7. The time of DepoDur injection. 8. The amount of pain medications used in the 0-2 hour time interval after injection, 2-4 hours, and each subsequent 4 hour interval. 9. Pain scores will be recorded with vital signs. (The pain score is from 1 to 10 and is asked orally to patients. This is part of the standard of care). In a one-to-one randomization, patients will receive either a 10 or 15 mg dose of DepoDur at the time of surgery Each patient will be provided with a morphine PCA (patient controlled analgesia) system postoperatively and then oral analgesics as appropriate. Analgesic requirements in morphine equivalents will be recorded. Comparison between the 10 and 15 mg dose will be done as to analgesic effectiveness and safety. Post-operative orders (for 48 hours) will include epidural narcotic protocol to include. The following post-operative orders are standard of care. 1. Patient's bedside and chart will be identified as spinal narcotic. 2. Head of bed maintained at 30 degrees of elevation. 3. 0.4 mg of Narcan (naloxone) will be added to each liter of IV fluid 4. Counted respirations and pupil size to be included with vital signs 5. Pain scores with vital signs (The pain score is from 1 to 10 and is asked orally to patients. This is part of the standard of care). 6. Continuous pulse oxymetry measurement 7. Call House officer for respiratory rate of \<8 minute or changes in saturation as measured by pulse oxymetry. Current post-operative PCA orders usually start with 1 mg of morphine per cc with a seven to ten minute lockout. Based on work by Rawal \[2-3\], who demonstrated that small doses of Naloxone could help eliminate nuisance side effects of epidural narcotics such as localized pruritis, 0.4 mg of Naloxon will be added to each liter of IV fluid. Continuous pulse oxymetry should be used to monitor the patient's respiratory function for 48 hours after the last dose of the epidural narcotic. Post-operative vital signs will be obtained in the recovery room by anesthesia policy. Once the patient is transferred to the floor, vital signs would be obtained every hour for the first four hours and every four hours after that. The standard of care involves providing patients after lumbar surgery with the best pain relief possible. This can be done in a number of different ways. The use of Duramorph has been possible for many years. It has not been used recently only because of the need to re-dose. The pain relief provided by the epidural narcotic is detailed in the literature. What will be altered through this study is the addition of the long acting epidural narcotic, DepoDur. This will potentially provide for sustained pain relief for 48 hours. Usually by 48 hours postoperatively, the patient is starting to improve to a point of being able to be maintained on oral analgesics. The remainder of the study is consistent with standard of care for epidural narcotics.

Interventions

An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.

Sponsors

EKR Therapeutics, Inc
CollaboratorINDUSTRY
University of Rochester
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All mentally competent patients over the age of 18 undergoing lumbar surgery at L3-S1 who would be expected to be hospitalized for greater than 48 hours would be eligible for this study.

Exclusion criteria

* Patients less than 18 years old, those not able to give consent, prisoners, patients with allergies to narcotic analgesics, and pregnant women will be excluded. Women who are pregnant or are not practicing medically acceptable contraception (a pregnancy test is used pre-operatively as part of standard of care). Patients who experience complications during the surgery (e.g., major hemorrhage, dural puncture) will not receive the study drug.

Design outcomes

Primary

MeasureTime frame
Number of Patients Enrolled and Recieving Injection0-48 hours postoperatively

Countries

United States

Participant flow

Participants by arm

ArmCount
Injection
DepoDur Injection
98
Total98

Baseline characteristics

CharacteristicInjection
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
32 Participants
Age, Categorical
Between 18 and 65 years
66 Participants
Age, Continuous60 years
STANDARD_DEVIATION 13.7
Region of Enrollment
United States
98 participants
Sex: Female, Male
Female
59 Participants
Sex: Female, Male
Male
39 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
5 / 98
serious
Total, serious adverse events
0 / 98

Outcome results

Primary

Number of Patients Enrolled and Recieving Injection

Time frame: 0-48 hours postoperatively

ArmMeasureValue (NUMBER)
InjectionNumber of Patients Enrolled and Recieving Injection98 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026